Skip to content
2000
Volume 20, Issue 10
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

At the blood-brain barrier, ATP-binding cassette (ABC) transporters, such as, P-glycoprotein (MDR1, ABCB1) and breast cancer related protein (BCRP, ABCG2) limit CNS uptake of foreign chemicals. Thus, they are neuroprotective, but they also distinguish poorly between neurotoxicants and therapeutic drugs. So they are major obstacles to CNS pharmacotherapy. The present review is focused on new findings in animal models in vitro and in vivo showing that basal transport activity of P-glycoprotein and Bcrp can be rapidly and transiently reduced through targeting of specific signaling pathways within the brain capillary endothelium. Three pathways have been identified: estrogen signaling to Bcrp, vascular endothelial growth factor signaling to P-glycoprotein and TNFα/PKC/ sphingolipid signaling to P-glycoprotein. Translation of these results to the clinic could provide improved pharmacotherapy for a number of CNS diseases, including, brain cancer, neuroAIDS and epilepsy.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/13816128113199990457
2014-03-01
2025-04-09
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/13816128113199990457
Loading

  • Article Type:
    Research Article
Keyword(s): ABC transporters; Blood-brain barrier; Drug delivery; efflux pumps; Neuroprotection; P-gp
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test